Subscribe to our Newsletters !!

    Drug Discovery

    Researchers distinguish aggravates that square replication of COVID-19 infection

    Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract. The inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus’s capacity to proliferate. The very promising drug candidates – like

    Drug discovery pipeline to exploit transcription factors for cancer therapy

    Cancer is a major cause of death and among the most complicated challenges to contemporary medication. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up firm QUANTRO Therapeutics tries to radically change the precision and range of cell-based drug screening. QUANTRO’s

    Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups

    HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated

    CARE consortium dispatches to quicken drug discovery and improvement for COVID-19

    Using a grant approximately $77.7 million, CARE is funded by cash donations by the European Union (EU) and money and in-kind contributions from Australian European Federation of Pharmaceutical Industries and Associations (EFPIA) businesses and three IMI-Associated Partners. CARE is a five-year project bringing together 37 partners from Belgium, China, Denmark, France, Germany, the Netherlands, Poland,

    Novel medication could improve future and quality for patients with difficult to-treat malignant growths

    The Sheffield researchers founded the spin-out Modulus Oncology with a group of experienced biotech entrepreneurs to fast-track the drug into clinical testing over two decades. The researchers founded the spin-out firm Modulus Oncology, along with a team of seasoned biotech entrepreneurs, to fast-track the drug into clinical testing over two years. The Sheffield team made

    Innovations Assist Compound Management in Pharma Drug Discovery

    Ziath has released a module to enable their Mirage, Cube or Express tube readers to decode Brooks Acoustix tubes. Acoustix is a small sample tube with a screw cap which is increasingly favored for storage of novel compounds in solution in large compound stores. It is also compatible with the latest generation of Labcyte Echo

    Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

    In this new role, Stewart will work as part of the Executive staff to drive Adaptate’s Business and Corporate Development activities. Stewart Kay, CBO, Adaptate Biotherapeutics Adaptate is developing a range of therapeutic antibodies that recognize drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells

    CN Bio declares dispatch of medication digestion and wellbeing poisonousness testing administrations

    Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway. The new services will incorporate the Company’s advanced Liver-on-Chip technology and experience in the field to enable researchers to create predictive and human-relevant data, improving the translatability from discovery to clinic, and hastening

    ATCC presents new product with launch of SARS-CoV-2 external control unit

    The ready-to-run kit provides controls in the rapidly changing COVID-19 testing landscape as a workflow-optimized kit with complete genome coverage that is widely compatible with most commercial and laboratory-developed tests. Federal regulation requires that clinical laboratories assess the performance of their testing applications. This new ATCC kit is a practical, kitted solution clinical laboratories can

    Jellagen dispatches JellaGel™, the principal Collagen Type 0 Hydrogel taking available driving Extracellular Matrix

    Jellagen® Limited, a biotechnology company manufacturing high-value Collagen Type 0 derived from jellyfish, announce the launch of their JellaGel™ Hydrogel. 3-dimensaional Hydrogels make it possible for cells to grow and interact with all of their surroundings that makes a massive difference. Cells grown in a 3D model have been shown to be more natural, with

    Corning to feature most current product in 3D cell culture portfolio at SLAS2021

    Corning Incorporated will highlight its hottest technologies that support the advancement of 3D cell culture, automation, and drug discovery in this year’s virtual Society for Laboratory Automation and Screening (SLAS) seminar on Jan. 25 through 27. Now more than ever, tools used to ease scale-up, reproducibility, and consistency of 3D cell culture are helping empower